Sarilumab治疗TNF抑制剂难治性类风湿关节炎5年长期安全性与疗效
本研究评估Sarilumab在TNF抑制剂难治性类风湿关节炎(RA)患者中超过5年的长期安全性和疗效。TARGET随机对照试验中546例患者,454例(83%)在EXTEND开放标签扩展研究中接受Sarilumab治疗,累计观察1654.8患者年。结果显示长期安全性特征与既往研究一致,疗效持续5年。
要点
- Sarilumab在TNFi难治性RA中5年安全性特征与既往研究及上市后报告一致。
- 临床疗效持续至5年随访,1次与超过1次TNFi失败患者疗效相似。
- 中性粒细胞减少是最常见不良事件,发生率15.3/100患者年。
核心结论
- 在TNF抑制剂难治性RA患者中,Sarilumab长期安全性特征与既往临床研究和上市后报告一致,疗效持续5年。
研究设计与样本
- TARGET随机对照试验(NCT01709578)中接受双盲安慰剂或Sarilumab 150或200 mg每2周联合csDMARDs的546例患者,纳入EXTEND开放标签扩展研究(NCT01146652)接受开放标签Sarilumab 200 mg每2周联合csDMARDs。
- 开放标签扩展研究中允许研究者判断或方案规定的安全性顾虑下减量至150 mg每2周。
- 安全性通过治疗中出现的不良事件、实验室异常和临床疾病活动评分评估,所有统计均为描述性。
主要发现
- 546例患者中454例(83%)在开放标签扩展研究中接受Sarilumab治疗,累计观察1654.8患者年(n=521),268例(51%)暴露≥4年。
- 每100患者年不良事件、导致停药的不良事件、感染和严重感染发生率分别为160.4、8.1、57.8和3.9。
- 中性粒细胞减少是最常见不良事件(15.3/100患者年),74例(14.2%)观察到绝对中性粒细胞计数<1000 cells/mm3(3/4级中性粒细胞减少),其中48例在治疗中恢复正常。
- 临床疗效持续至5年随访,1次与超过1次TNFi失败患者疗效相似,维持200 mg与减量至150 mg患者疗效相似。
临床怎么用
- Sarilumab可用于TNF抑制剂难治性RA患者的长期治疗,5年疗效持续且安全性可控。
- 治疗期间需监测中性粒细胞计数,3/4级中性粒细胞减少多数可在治疗中恢复。
局限性
- 所有统计均为描述性,未进行组间统计比较。
- 开放标签扩展研究设计可能存在选择偏倚,仅83%的随机对照试验患者进入扩展研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this study was to evaluate the long-term safety and efficacy of sarilumab over 5 years in patients with RA refractory to TNF inhibitors (TNFis). METHODS: Patients in the 24-week randomized controlled trial (RCT) TARGET (NCT01709578) who received double-blind placebo or sarilumab 150 or 200 mg every 2 weeks (q2w), plus conventional synthetic DMARDs (csDMARDs), were eligible to receive open-label sarilumab 200 mg q2w plus csDMARDs in the open-label extension (OLE), EXTEND (NCT01146652). OLE dose reduction to 150 mg q2w was permitted per investigators' judgement or protocol-mandated safety concerns. Safety and efficacy were assessed through treatment-emergent adverse events (AEs), laboratory abnormalities and clinical DASs. All statistics are descriptive. RESULTS: Of 546 patients, 454 (83%) were treated with sarilumab in the OLE. The cumulative observation period was 1654.8 patient-years (PY; n = 521); 268 patients (51%) had ≥4 years' exposure. Incidence rates per 100 PY of AEs, and AEs leading to discontinuation, infection and serious infection were 160.4, 8.1, 57.8 and 3.9, respectively. Neutropenia was the most common AE (15.3 per 100 PY). An absolute neutrophil count of <1000 cells/mm3 (Grade 3/4 neutropenia) was observed in 74 patients (14.2%) and normalized on treatment in 48. Clinical efficacy was sustained through 5 years' follow-up. Efficacy was similar for patients with 1 and >1 TNFi failure, and similar for patients who either remained on 200 mg or reduced to 150 mg. CONCLUSION: In patients with RA refractory to TNFi, sarilumab's long-term term safety profile was consistent with previous clinical studies and post-marketing reports. Efficacy was sustained over 5 years. TRIAL REGISTRATION: TARGET, ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT01709578, NCT01709578; EXTEND, ClinicalTrials.gov, https://www.clinicaltrials.gov/ct2/show/NCT01146652, NCT01146652.
引用
- Fleischmann R, Genovese MC, Maslova K, et al. Long-term safety and efficacy of sarilumab over 5 years in patients with rheumatoid arthritis refractory to TNF inhibitors. Rheumatology (Oxford). 2021. PMID: 33871596. doi:10.1093/rheumatology/keab355
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。